Last reviewed · How we verify
C.E.R.A.
C.E.R.A. is a continuous erythropoietin receptor activator.
C.E.R.A. is a continuous erythropoietin receptor activator. Used for Anemia associated with chronic kidney disease.
At a glance
| Generic name | C.E.R.A. |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Erythropoiesis-stimulating agent |
| Target | Erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
It works by continuously activating the erythropoietin receptor, which stimulates erythropoiesis.
Approved indications
- Anemia associated with chronic kidney disease
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA. (PHASE3)
- A Study of Subcutaneous Mircera for the Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease Not on Dialysis (PHASE3)
- A Study of Once Monthly Intravenous or Subcutaneous Mircera in Participants With Chronic Kidney Disease on Hemodialysis. (PHASE3)
- A Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) for the Treatment of Chronic Renal Anemia in Participants With Diabetic Nephropathy (PHASE4)
- A Study of Subcutaneous C.E.R.A. for the Maintenance of Hemoglobin Levels in Participants With Chronic Renal Anemia Not on Dialysis. (PHASE3)
- A Study of Mircera in Anemic Patients With Multiple Myeloma (PHASE1, PHASE2)
- A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia (PHASE3)
- A Study of Mircera (C.E.R.A.) in Patients With Pre-Dialysis Chronic Renal Anemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- C.E.R.A. CI brief — competitive landscape report
- C.E.R.A. updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI